Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel
Josu de la Fuente(Imperial College Healthcare NHS Trust), Franco Locatelli(Bambino Gesù Children's Hospital), Donna A. Wall(University of Manitoba), Nanxin Li(Genomics Institute of the Novartis Research Foundation), Mattia Algeri(Bambino Gesù Children's Hospital), Haydar Frangoul(Children’s Hospital at TriStar Centennial), Ben Carpenter(The Royal Free Hospital), Wally R. Smith(Virginia Commonwealth University), Roland Meisel(Heinrich Heine University Düsseldorf), Jaime Rubin(Vertex Pharmaceuticals (United States)), Peter Lang(STZ eyetrial), Amanda M. Li(BC Children's Hospital), Kevin H.M. Kuo(University Health Network), Robert I. Liem(Lurie Children's Hospital), Ami J. Shah(University of California, Los Angeles), Hayley Merkeley(University of British Columbia), Selim Corbacioglu(Unknown), Janet L. Kwiatkowski(Children's Hospital of Philadelphia), William Hobbs(Vertex Pharmaceuticals (United States)), Siyu Zhang(Xi'an Jiaotong University), Puja Kohli(Brigham and Women's Hospital), Joachim Rupprecht(University of Tübingen), Markus Y. Mapara(Sheba Medical Center)
Cited by 3
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
|New England Journal of Medicine|2020|1.8k
Sickle cell disease
|Nature Reviews Disease Primers|2018|1.4k
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738